Xinmei N. Wang
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.
Journal: Clinical and translational science
Published: February 12, 2025
Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.
Journal: Frontiers in microbiology
Published: October 25, 2024
FL058, a novel β-lactamase inhibitor, increases the anti-Mycobacterium abscessus activity of imipenem.
Journal: International journal of antimicrobial agents
Published: August 09, 2024
In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales.
Journal: Frontiers in pharmacology
Published: August 24, 2023
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Journal: Investigational new drugs
Published: November 03, 2022
WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations.
Journal: Annals of translational medicine
Published: May 10, 2022
Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Journal: Immunopharmacology and immunotoxicology
Published: February 18, 2022
Establishment of a novel CNV-related prognostic signature predicting prognosis in patients with breast cancer.
Journal: Journal of ovarian research
Published: January 25, 2021
Last Updated: 09/26/2026